Participant characteristics among the 245 HCV RNA positive participants at the time of acute HCV detection are shown in Table 1. Cohort differences included a higher proportion with sexual acquisition and HIV infection in ATAHC, a higher proportion of Aboriginal ethnicity in HITS-p, and a higher proportion with an estimated duration of infection <26 weeks in the HEPCO study. The mean age was 33 years (standard deviation [SD], 10), 75% were male, 10% were of Aboriginal ethnicity, and 19% had HIV. Plasma IP-10 levels were available for 215 of Alectinib 245 individuals who were HCV RNA-positive at the time of acute HCV detection (Fig. 1). Plasma IP-10 levels at the

time of acute HCV detection ranged from 0 to 3,071 pg/mL (median 137 pg/mL; interquartile range [IQR]: 73,264; mean 245 ± 369 pg/mL).

Log plasma IP-10 levels at the time of acute HCV detection correlated with log HCV RNA levels (P < 0.001, r = 0.28, Supporting Fig. find more 1). The correlation between log HCV RNA and log IP-10 at the time of acute HCV detection differed by IL28B genotype. The correlation was significant in those with the favorable CC genotype (rs12979860) but borderline in those with the CT/TT genotype (CC: r = 0.41, P < 0.001; CT/TT: r = 0.21, P = 0.056; Supporting Fig. 1). Individuals with HIV had significantly higher median (239 versus 126 pg/mL, P < 0.001, Fig. 2B) and mean plasma IP-10 levels (390 ± 78 pg/mL versus 208 ± 24 pg/mL, P = 0.004)

at the time of acute HCV detection than those with HCV alone. Median plasma IP-10 levels were not significantly different between those with unfavorable selleck screening library and favorable IL28B genotypes (rs8099917: GT/GG, 153 pg/mL versus TT 141 pg/mL, P = 0.120; rs12979860, CT/TT, 143 pg/mL versus TT 147 pg/mL, P = 0.188, Fig. 2). However, mean plasma IP-10 levels were higher among those with an unfavorable IL28B genotype (rs8099917: GG/GT 350 ± 62 pg/mL versus TT 193 ± 17 pg/mL, P = 0.019; rs12979860: TT/CT 294 ± 46 pg/mL versus CC 197 ± 21 pg/mL, P = 0.057). Information on ALT levels, documented HCV illness with jaundice, and IP-10 were available for 113 participants from ATAHC (this information was not systematically collected from other cohorts). Among this subset (n = 113), both median and mean plasma IP-10 levels were higher in those with ALT >100 U/L at the time of acute HCV detection (stratified by median ALT of 100 U/L; median: 242 versus 162 pg/mL, P = 0.003; mean: 383 versus 182 pg/mL, P = 0.010). There was no significant difference in median and mean plasma IP-10 levels among those with and without documented HCV illness with jaundice (n = 24, 21%; median: 196 versus 173 pg/mL, P = 0.214; mean: 378 versus 280 pg/mL, P = 0.210). Factors independently associated with plasma IP-10 levels ≥150 pg/mL (median) at the time of acute HCV detection were assessed (Table 2).